Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
31
Recruiting, industry sponsors, Respiratory, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed646
31 trials
Showing 1 to 25, recently updated first.
- A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07822334 · 104 participants (planned) · Start Oct 28, 2026 · Primary completion Oct 11, 2028
Drug: RO7830698; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD); Healthy Participants
Sites: Wythenshawe, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT06433921 · 84 participants (planned) · Start Aug 14, 2024 · Primary completion Apr 16, 2027
Drug: Salbutamol HFA-152a; Salbutamol HFA-134a and 1 more · For: Asthma; Mild Asthma
Sites: Manchester, United Kingdom
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07915024 · 47 participants (planned) · Start Aug 6, 2026 · Primary completion Nov 2026
Drug: HSK31858 tablet; Placebo and 1 more · For: Non-cystic Fibrosis Bronchiectasis (NCFBE)
Sites: Jinan, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07915011 · 24 participants (planned) · Start May 26, 2026 · Primary completion Nov 2026
Drug: HSK31858 tablets · For: Non-cystic Fibrosis Bronchiectasis (NCFBE)
Sites: Zhenzhou, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07913009 · 30 participants (planned) · Start Mar 16, 2026 · Primary completion Dec 2026
Drug: HSK31858 tablets · For: Non-cystic Fibrosis Bronchiectasis (NCFBE)
Sites: Zhenzhou, China
- A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07660731 · 133 participants (planned) · Start Jun 17, 2026 · Primary completion Mar 30, 2027
Drug: PF-08103402; Placebo and 1 more · For: Healthy Volunteer Study; Healthy Adults; Healthy Participants and 1 more
Sites: New Haven, Connecticut; Brussels, Belgium
35Pharma Inc., a GSK companyIndustry
NCT07143448 · 90 participants (planned) · Start Aug 19, 2026 · Primary completion Mar 2028
Drug: HS235 · For: Pulmonary Arterial Hypertension
Sites: Tampa, Florida; Boston, Massachusetts; Providence, Rhode Island · 7 sites in all
- A Study of HB0056 in Adult Participants With Moderate to Severe AsthmaPivotal-lookingRecruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07899996 · 160 participants (planned) · Start Aug 21, 2025 · Primary completion Aug 1, 2027
Drug: Placebo; HB0056 · For: Asthma
Sites: Beijing, China · 2 sites in all
Kither Biotech SrlIndustry
NCT07668518 · 36 participants (planned) · Start Aug 5, 2026 · Primary completion Mar 31, 2027
Drug: KIT2014; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Charlestown, Australia; Sydney, Australia; Camberwell, Australia
- Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07283770 · 152 participants (planned) · Start Dec 9, 2025 · Primary completion Jul 12, 2027
Drug: VX-581; Placebo and 5 more · For: Cystic Fibrosis
Sites: Overland Park, Kansas
- Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With AsthmaPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07851623 · 120 participants (planned) · Start Oct 2, 2026 · Primary completion Dec 27, 2027
Drug: CHF10136; CHF10136 matched placebo · For: Asthma; Healthy Volunteers
Sites: Leeds, United Kingdom; London, United Kingdom; Manchester, United Kingdom
- Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07437105 · 160 participants (planned) · Start Feb 25, 2026 · Primary completion Jun 26, 2027
Drug: VX-272; Placebo and 2 more · For: Cystic Fibrosis
Sites: Tempe, Arizona
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07732023 · 36 participants (planned) · Start Aug 25, 2026 · Primary completion Jul 30, 2028
Drug: SKB575; Placebo · For: Asthma (Diagnosis)
Sites: Chengdu, China · 2 sites in all
RIGImmune Inc.Industry
NCT07488897 · 82 participants (planned) · Start Feb 9, 2026 · Primary completion Feb 2027
Drug: RIG-101 · For: Healthy Adult Participants; Asthma Exacerbation; Safety and Efficacy
Sites: London, United Kingdom; Manchester, United Kingdom
Diagonal Therapeutics, Inc.Industry
NCT07623525 · 93 participants (planned) · Start Jun 4, 2026 · Primary completion Nov 30, 2027
Drug: DIAG723 · For: Hereditary Hemorrhagic Telangiectasia; Pulmonary Arterial Hypertension
Sites: Camperdown, Australia; Randwick, Australia; Herston, Australia · 11 sites in all
Shanghai Synvida Biotechnology Co.,Ltd.Industry
NCT06267183 · 53 participants (planned) · Start Jan 12, 2024 · Primary completion Nov 30, 2026
Drug: SV001; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Shanghai, China
- Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Atisama TherapeuticsIndustry
NCT07285122 · 105 participants (planned) · Start Feb 16, 2026 · Primary completion Oct 2027
Drug: RB042; Placebo inhalation solution · For: Healthy; Healthy Smoker; COPD (Chronic Obstructive Pulmonary Disease) and 1 more
Sites: Nedlands, Australia
SMSbiotechIndustry
NCT06986070 · 18 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 2026
Drug: Stem cells · For: Chronic Obstructive Lung Disease
Sites: Melbourne, Australia
Prana Therapies IncIndustry
NCT07245368 · 96 participants (planned) · Start Nov 4, 2025 · Primary completion Oct 1, 2026
Drug: PRA-216; Placebo · For: Mild to Moderate Asthma
Sites: Botany, Australia; Camberwell, Australia; Clayton, Australia · 8 sites in all
Pharmosa Biopharm Inc.Industry
NCT06429930 · 40 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 31, 2026
Drug: L608 Liposomal inhalation suspension; Placebo Solution · For: Healthy Adult Participants
Sites: Christchurch, New Zealand
Bambusa TherapeuticsIndustry
NCT07288554 · 68 participants (planned) · Start Sep 5, 2025 · Primary completion Dec 31, 2026
Drug: BBT002; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Hefei, China; Guangzhou, China; Jiangmen, China · 11 sites in all
Bambusa TherapeuticsIndustry
NCT07436949 · 64 participants (planned) · Start Mar 2, 2026 · Primary completion Dec 31, 2027
Drug: BBT002; Placebo · For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Sites: Beijing, China; Guangzhou, China; Changsha, China · 12 sites in all
- A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06649110 · 232 participants (planned) · Start Oct 24, 2024 · Primary completion Nov 29, 2028
Drug: LTP; Placebo · For: Healthy Volunteers, Pulmonary Arterial Hypertension
Sites: Scottsdale, Arizona; Orange, California; Stanford, California · 87 sites in all
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07567872 · 48 participants (planned) · Start Jul 9, 2026 · Primary completion Sep 2026
Drug: HRS-9821 Powder for Inhalation; Placebo · For: COPD
Sites: Chengdu, China
- First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected PatientsPivotal-lookingRecruiting
Centauri Therapeutics LimitedIndustry
NCT07708116 · 104 participants (planned) · Start Jun 16, 2026 · Primary completion Dec 31, 2027
Drug: Placebo; CTX-187 · For: Bronchiectasis Adult; Bronchiectasis With Pseudomonas Aeruginosa Colonization; Bacterial Infections
Sites: Groningen, Netherlands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.